The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients

We presented the rationale for the use of thymosin α1 as prophylaxis of severe COVID-19 in cancer patients undergoing active treatment, constituting the background for the PROTHYMOS study, a prospective, multicenter, open-label, Phase II randomized study, currently in its start-up phase (Eudract no....

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Future Oncol
Главные авторы: Bersanelli, Melissa, Giannarelli, Diana, Leonetti, Alessandro, Buti, Sebastiano, Tiseo, Marcello, Nouvenne, Antonio, Ticinesi, Andrea, Meschi, Tiziana, Procopio, Giuseppe, Danielli, Riccardo
Формат: Artigo
Язык:Inglês
Опубликовано: Future Medicine Ltd 2021
Предметы:
Special Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7874885/
https://ncbi.nlm.nih.gov/pubmed/33538178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2020-0754
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы